Elan Shares Climb on $3.25B Biogen's Tysabri Deal

Feb. 6 (Bloomberg) -- Bloomberg's Caroline Hyde reports on what is next for Elan Corp. as Biogen Idec Inc. agreed to acquire the company's stake in the multiple sclerosis drug Tysabri for $3.25 billion in cash plus future royalties. She speaks on Bloomberg Television's "The Pulse."

Alan Patricof: It’s Hard to Predict Anything About Trump
07:01 - Greycroft Partners Managing Director Alan Patricof and 500 Startups Founding Partner Dave McClure discuss VC investing, the impact President Trump may have on the tech sector and the merger and acquisition atmosphere. They speak on “Bloomberg Technology.” (Source: Bloomberg)
  • Apple Sues Qualcomm Over Patent Royalties
  • NAFTA Could Stand An Update: Ex-Canada Ambassador to U.S.
  • Full Show: Bloomberg Businessweek (01/20)